Consider the following medical report that includes the patient's historical health records. Use it to predict the disease that the patient is high likely exposed to. 

 Medical Report: history of present illness: ms. is a 57-year-old female with metastatic renal cell carcinoma being admitted today for cycle 1, week 2, high-dose il-2 therapy. her oncologic history began in when a torso ct to evaluate worsening edema and anemia revealed a 16-cm mass in her right kidney. there was a prominent lymph node between the aorta and vena cava and a possible bone metastasis in the l3 vertebral body. chest ct revealed a 5 x 3.5-cm soft tissue mass in the sternum. multiple small lung nodules were also noted. she underwent preoperative embolization of the renal mass in , followed by right hand-assisted laparoscopic nephrectomy and biopsy of the chest wall lesion on , by dr. . pathology revealed renal cell carcinoma, clear cell type, predominately grade 3 with focal sarcomatoid areas. tumor was 15 cm in size and invaded the renal capsule. there was no renal vein invasion and margins were negative. biopsy of the chest wall lesion was consistent with metastatic renal cell carcinoma. she was referred here to discuss treatment options and planned for high-dose il-2 therapy. pretreatment torso ct revealed a small-to-moderate pericardial effusion. an echo confirmed a small effusion without tamponade. she then underwent a vats pericardial window and left upper lobe wedge resection on , due to concern for worsening effusion during il-2 thick high-dose il-2 therapy. she otherwise passed stress test and pfts and began cycle 1, week 1 high-dose il-2 therapy in , receiving doses with course complicated by toxic encephalopathy and acute renal failure. she is now recovered is ready for week 2 of therapy. past medical history: hypertension, renal cell cancer as above, diabetes, hyperlipidemia, status post c-section 26 years ago, status post gallbladder surgery and primary carcinoid tumor of the lung diagnosed on . allergies: no known drug allergies. medications: toprol 200 mg p.o. daily on hold. micardis 80/25 mg daily on hold, januvia 100 mg p.o. daily, crestor 10 mg daily, niaspan 750 mg daily, clonidine 0.3 mg b.i.d., metformin 500 mg p.o. b.i.d. on hold. physical examination: general: well-appearing female in no acute distress. performance status zero. vital signs: 96.7, 71, 20, 130/80. o2 saturation 98% on room air. heent: normocephalic, atraumatic. sclerae anicteric. moist oral mucosa without lesions. neck: supple without masses. lymph nodes: no cervical, supraclavicular, bilateral axillary or bilateral inguinal lymphadenopathy. heart: regular rate and rhythm. s1, s2. chest: decreased breath sounds at the left base; otherwise clear. abdomen: flat, soft, nontender. no hsm or masses. extremities: no edema. skin: intact. neurologic: nonfocal. laboratory data: admission labs: wbc 8.3, hemoglobin 12, hematocrit 35, platelet count 283,000. inr 1.1. bun 16, creatinine 1.1, sodium 39, potassium 4.3, chloride 100, co2 25, glucose 208, alt 29, ast 25, ck 23, albumin 3.8, calcium 9.2, phosphorus 3.1, magnesium 1.8. hospital course: ms. was admitted and underwent central line placement to begin therapy. her admission weight was 101.3 kg and she received interleukin-2 60.8 million units iv every 8 hours x 14 potential doses. during this week she received 7 of 14 doses, the doses held due to by shock and atrial fibrillation. side effects early in the week included nausea and vomiting improved with antiemetic therapy; diarrhea improved with lomotil therapy; hypotension on treatment day #2 improved with fluid boluses. on treatment day #3 she developed mild restlessness and confusion felt to be consistent with toxic encephalopathy and had il-2 placed on hold until her mental status had improved. on treatment day #4, approximately 5 hours after her dose of il-2 therapy, she developed hypotension and was placed on neo- synephrine to a max dose with addition of dopamine to max 6 mcg/kg per minute. systolic blood pressure remained in the 75- 90 range. icu consult was obtained at that time, given need for further pressor requirement. in addition, she converted to rapid atrial fibrillation. she was weaned from dopamine with the addition of levophed and weaned off pressors over the next several hours with return to the floor on treatment day #5. on treatment day #5 she was noted to have an elevated ck to 143 with a ck-mb of 14 and troponin of 0.23. this was in the setting of acute renal failure with a creatinine of 5.5. on treatment day #6, her ck had normalized at 45 with normal ck-mb level. she was subsequently discharged on . during this week she developed acute renal failure with a peak creatinine of 5.5 with associated oliguria. metabolic acidosis was noted with minimum bicarb of 16 improved with bicarbonate replacement intravenously. electrolytes were monitored and repleted per protocol. strict intakes and outputs and serum chemistries were maintained. iv fluids were decreased, given concern for diastolic dysfunction the setting of acute renal failure. she developed a transaminitis with a peak alt of 111 and a peak ast of 139 improved to within normal limits at the time of discharge. she developed hyperbilirubinemia with a peak bilirubin of 7.1, improved to 3.0 at the time of discharge. she was anemic without need for packed red blood cell transfusion. she had no thrombocytopenia noted. her inr was elevated to 2.4 on treatment day #3; improved to 1.3 at the time of discharge. as noted on treatment day #4, she developed shock related to capillary leak syndrome requiring initiation of neo- synephrine to max 3.5 mcg/kg per minute, as well as the addition of dopamine 6 mcg/kg per minute. continuous blood pressure bedside and central telemetry monitoring were instituted. she went into rapid atrial fibrillation and required transfer to the icu where dopamine was weaned off and levophed was used until the blood pressure stabilized. il-2 therapy was placed on hold at that time and was not restarted. once il-2 therapy was complete her blood pressure improved without further shock noted. by she recovered from side effects to allow for discharge to home. condition on discharge: stable. discharge status: to home with her family. discharge diagnoses: metastatic renal cell carcinoma, status post cycle 1 week 2 high-dose il-2 therapy complicated by shock, acute renal failure and toxic encephalopathy. discharge medications: lasix 20 mg p.o. daily x 5 days or until you reach pretreatment weight, tylenol 1-2 tablets q.i.d. p.r.n. fever or pain, zantac 150 mg p.o. b.i.d. p.r.n. heartburn, lorazepam 1 mg t.i.d. p.r.n. nausea/vomiting, benadryl 25-50 mg q.i.d. p.r.n. pruritus, compazine 10 mg q.i.d. p.r.n. nausea/vomiting, keflex 500 mg p.o. b.i.d. times 5 days, lomotil 1-2 tabs q.i.d. p.r.n. diarrhea, eucerin cream topically, sarna lotion topically. follow-up plans: ms. will return in 4 weeks after ct scans to assess disease response. , dictated by: medquist36 d: 12:47:06 t: 16:37:08 job#: procedure: venous catheterization, not elsewhere classified high-dose infusion interleukin-2 [il-2] diagnoses: acidosis toxic encephalopathy unspecified essential hypertension diabetes mellitus without mention of complication, type ii or unspecified type, not stated as uncontrolled acute kidney failure, unspecified atrial fibrillation malignant neoplasm of kidney, except pelvis hypotension, unspecified antineoplastic and immunosuppressive drugs causing adverse effects in therapeutic use diarrhea secondary malignant neoplasm of lung secondary malignant neoplasm of bone and bone marrow encounter for antineoplastic immunotherapy 

Answer: The patient is high likely exposed to